HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Edmonds, C. Articles by Tellez, M Search for Related Content PubMed Articles by Edmonds, C. Articles by Tellez, M

Treatment of Graves' disease by carbimazole: high dose with thyroxine compared to titration dose

Edmonds CJ, Tellez M. Treatment of Graves' disease by carbimazole: high dose with thyroxine compared to titration dose. Eur J Endocrinol 1994;131:120–4. ISSN 0804–4643

A comparative study of high-dose (HD, carbimazole 60 mg plus thyroxine 100–150 µg daily) and titration-dose (TD) regimens of carbimazole was carried out in 70 patients with Graves' disease, the patients being assigned randomly to one or other regimen. The treatment was given for 1 year and follow-up was for 2 years after stopping treatment. In both groups, recurrence of hyperthyroidism occurred, most commonly during the first 6 months (35% of HD and 44% of TD). By 2 years after stopping treatment, recurrence had occurred in 50% of the HD and 66% of the TD group. The differences were not significant. Thyroid antibodies, serum thyroglobulin and pertechnetate uptake fell similarly in both groups during treatment. Cigarette smoking was similar in both the groups and did not influence the frequency of relapse. In both HD and TD groups, when relapsing patients were examined according to whether they relapsed early (within 6 months or less) or late it was found that those who relapsed late were, in respect of goitre size, pertechnetate uptake and presence of detectable plasma TSH, similar to the patients who did not relapse at all. In conclusion, the changes in the measured variables and the progress of the patients was similar whether treated by the HD or TD regimen.

CJ Edmonds, Northwick Park Hospital, Watford Road, Harrow, Middlesex HA1 3UJ, UK

This article has been cited by other articles:

				S. Razvi, B. Vaidya, P. Perros, and S. H S Pearce What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur. J. Endocrinol., June 1, 2006; 154(6): 783 - 786. [Abstract] [Full Text] [PDF]

				P. Abraham, A. Avenell, C. M Park, W. A Watson, and J. S Bevan A systematic review of drug therapy for Graves' hyperthyroidism Eur. J. Endocrinol., October 1, 2005; 153(4): 489 - 498. [Abstract] [Full Text] [PDF]

				R. S. Rittmaster, E. C. Abbott, R. Douglas, M. L. Givner, L. Lehmann, S. Reddy, S. R. Salisbury, A. H. Shlossberg, M. H. Tan, and S. E. York Effect of Methimazole, with or without L-Thyroxine, on Remission Rates in Graves' Disease J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 814 - 818. [Abstract] [Full Text]

				A. Lucas, I. Salinas, F. Rius, E. Pizarro, M.L. Granada, M. Foz, and A. SanmartI Medical Therapy of Graves' Disease: Does Thyroxine Prevent Recurrence of Hyperthyroidism? J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2410 - 2413. [Abstract] [Full Text] [PDF]

				N. S. Glaser and D. M. Styne Predictors of Early Remission of Hyperthyroidism in Children J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1719 - 1726. [Abstract] [Full Text] [PDF]